Skip to main content
. 2021 Aug 25;8(9):ofab439. doi: 10.1093/ofid/ofab439

Figure 2.

Figure 2.

Virologic outcomes at week 256 by United States Food and Drug Administration Snapshot algorithm. aParticipants in extension-switch groups switched to cabotegravir + rilpivirine long-acting at week 100. Abbreviations: c/mL, copies per milliliter; IM, intramuscular; Q4W, every 4 weeks; Q8W, every 8 weeks.